My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Yes Bank declines on reports of $1 billion QIP issue plan
Aug 11,2016

Meanwhile, the S&P BSE Sensex was up 97.88 points or 0.35% at 27,872.76.

On BSE, so far 73,000 shares were traded in the counter as against average daily volume of 2.08 lakh shares in the past one quarter. The stock hit a high of Rs 1,268 and a low of Rs 1,237 so far during the day. The stock had hit a 52-week low of Rs 590 on 24 August 2015. The stock had hit a record high of Rs 1,269 on 8 August 2016. The stock had outperformed the market over the past one month till 10 August 2016, surging 13.02% compared with 2.39% rise in the Sensex. The scrip had also outperformed the market in past one quarter, advancing 33.16% as against Sensexs 7.77% rise.

The large-cap bank has equity capital of Rs 421.22 crore. Face value per share is Rs 10.

Media reports suggested that Yes Bank is contemplating a $1 billion share sale to institutional investors through qualified institutional placement (QIP) to support its expansion plans. The issue is expected to be launched within 30 days, reports suggested. It may be recalled that Yes Banks board of directors in April 2016 approved the renewal of its capital raising plan of upto $1 billion through appropriate capital raising modes.

Yes Banks net profit rose 32.8% to Rs 731.80 crore on 25.4% growth in total income to Rs 4762.83 crore in Q1 June 2016 over Q1 June 2015.

Yes Bank is one of the leading private sector banks in India.

Powered by Capital Market - Live News

Yes Bank declines on reports of $1 billion QIP plan
Aug 11,2016

Meanwhile, the S&P BSE Sensex was up 97.88 points or 0.35% at 27,872.76.

On BSE, so far 73,000 shares were traded in the counter as against average daily volume of 2.08 lakh shares in the past one quarter. The stock hit a high of Rs 1,268 and a low of Rs 1,237 so far during the day. The stock had hit a 52-week low of Rs 590 on 24 August 2015. The stock had hit a record high of Rs 1,269 on 8 August 2016. The stock had outperformed the market over the past one month till 10 August 2016, surging 13.02% compared with 2.39% rise in the Sensex. The scrip had also outperformed the market in past one quarter, advancing 33.16% as against Sensexs 7.77% rise.

The large-cap bank has equity capital of Rs 421.22 crore. Face value per share is Rs 10.

Media reports suggested that Yes Bank is contemplating a $1 billion share sale to institutional investors through qualified institutional placement (QIP) to support its expansion plans. The issue is expected to be launched within 30 days, reports suggested. It may be recalled that Yes Banks board of directors in April 2016 approved the renewal of its capital raising plan of upto $1 billion through appropriate capital raising modes.

Yes Banks net profit rose 32.8% to Rs 731.80 crore on 25.4% growth in total income to Rs 4762.83 crore in Q1 June 2016 over Q1 June 2015.

Yes Bank is one of the leading private sector banks in India.

Powered by Capital Market - Live News

Motherson Sumi Systems extends losses after brokerage downgrade
Aug 11,2016

Meanwhile, the BSE Sensex was up 108.37 points, or 0.39%, to 27,883.25.

On BSE, so far 3.57 lakh shares were traded in the counter, compared with average daily volume of 3.09 lakh shares in the past one quarter. The stock hit a high of Rs 326 and a low of Rs 310.20 so far during the day. The stock hit a 52-week high of Rs 358.55 on 2 August 2016. The stock hit a 52-week low of Rs 206.20 on 25 February 2016. The stock had outperformed the market over the past 30 days till 10 August 2016, rising 12.59% compared with 0.12% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 23.32% as against Sensexs 7.70% rise.

The large-cap company has equity capital of Rs 132.29 crore. Face value per share is Re 1.

A foreign brokerage has reportedly maintained sell rating on shares of Motherson Sumi Systems with a target price of Rs 255. Valuation looks expensive after recent rally, the brokerage reportedly said. The brokerage has reportedly cut financial year ending March 2017 (FY 2017) and financial year ending March 2018 (FY 2018) earnings per share estimates of the company by 5-8%.

Motherson Sumi Systems consolidated net profit rose 15.81% to Rs 439.36 crore on 16.12% increase in net sales to Rs 10352.33 crore in Q1 June 2016 over Q1 June 2015. The company said that the revenue was highest ever in a quarter. Consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) rose 20% to Rs 928 crore in Q1 June 2016 over Q1 June 2015. The company said that the growth was fuelled by strong performance across the major product divisions and geographies.

The result was announced during trading hours yesterday, 10 August 2016. The stock fell 6.42% to Rs 329.95 yesterday, 10 August 2016. The stock has fallen 9.10% in two sessions from Rs 352.60 on Tuesday, 9 August 2016.

Motherson Sumi Systems is one of the worlds fastest growing specialised automotive component manufacturing company for original equipment manufacturers (OEMs). It is a joint venture between Samvardhana Motherson Group and Sumitomo Wiring Systems (Japan).

Powered by Capital Market - Live News

Suven Life Sciences jumps after strong Q1 earnings
Aug 11,2016

The result was announced after market hours yesterday, 10 August 2016.

Meanwhile, the BSE Sensex was up 86.64 points, or 0.31%, to 27,861.52.

On BSE, so far 1.20 lakh shares were traded in the counter, compared with average daily volume of 60,192 shares in the past one quarter. The stock hit a high of Rs 213.90 and a low of Rs 206.15 so far during the day. The stock hit a 52-week high of Rs 308.70 on 5 October 2015. The stock hit a 52-week low of Rs 144.35 on 19 February 2016. The stock had underperformed the market over the past 30 days till 10 August 2016, falling 2.43% compared with 0.12% decline in the Sensex. The scrip had also underperformed the market in past one quarter, sliding 5.24% as against Sensexs 7.70% rise.

The small-cap company has equity capital of Rs 12.73 crore. Face value per share is Re 1.

Suven Life Sciences earnings before interest, taxes, depreciation and amortization (EBITDA) rose 56.34% to Rs 47.90 crore in Q1 June 2016 over Q1 June 2015. EBITDA margins were reported at 34.80% in Q1 June 2016, higher than 28.84% in Q1 June 2015.

The company said that its thrust on innovative research and development (R&D) in drug discovery continues with a spending of Rs 14.70 crore (10.67% on revenue) in Q1 June 2016.

Suven Life Sciences is a biopharmaceutical company specializing in drug discovery and developmental activities in central nervous system disorders and contract research and manufacturing services (CRAMS).

Powered by Capital Market - Live News

UltraTech Cement nudges lower, JP Associates surges after CCI nod for cement biz deal
Aug 11,2016

Shares of UltraTech Cement were down 0.1% at Rs 3,724.75. The stock hit a high of Rs 3,781.70 and a low of Rs 3,708.70 so far during the day.

Shares of Jaiprakash Associates were up 5.03% at Rs 11.69. The stock hit a high of Rs 11.72 and a low of Rs 10.94 so far during the day.

Meanwhile, the S&P BSE Sensex was up 86.51 points or 0.31% at 27,861.39.

Jaiprakash Associates (JAL) and UltraTech Cement had entered into an agreement in July 2016 whereby JAL had agreed to sell its cement plants spread across five states to UltraTech Cement for enterprise value of Rs 16189 crore. The board of directors of JAL and UltraTech Cement had approved for sale of cement business of JAL and its wholly-owned subsidiary Jaypee Cement Corporation (JCCL).

UltraTech Cement is a leading cement manufacturer in India. It is a part of the Aditya Birla Group. The companys consolidated net profit rose 29.2% to Rs 780.11 crore on 4.1% growth in net sales to Rs 6537.83 crore in Q1 June 2016 over Q1 June 2015.

Jaiprakash Associates is the flagship company of the Jaypee group and is engaged in engineering and construction, cement, real estate and hospitality businesses. The company reported net loss of Rs 1387.30 crore in Q4 March 2016, higher than net loss of Rs 858.07 crore in Q4 March 2015. Net sales declined 25.7% to Rs 1893.94 crore in Q4 March 2016 over Q4 March 2015.

Powered by Capital Market - Live News

Dilip Buildcon sees good debut
Aug 11,2016

The stock debuted at Rs 240, a premium of 9.59% over the initial public offer (IPO) price. So far the stock hit a high of Rs 253.95 and low of Rs 239.25. On BSE, so far 45.65 lakh shares changed hands in the counter.

Dilip Buildcon (DBL) had priced its initial public offer (IPO) at Rs 219 per share, the top end of the 214-219 per share price band for the issue. The DBL IPO ended on 3 August 2016. It received bids for 44.76 crore shares. The IPO was subscribed 20.95 times.

DBL is one of the leading road-focused engineering, procurement and construction (EPC) contractors in India. From the proceeds of the fresh issue, DBL has earmarked Rs 430 crore towards repayment of term loans of around Rs 203.60 crore, Rs 200 crore for meeting working capital requirements and rest for general corporate purpose.

DBLs consolidated net profit rose 124% to Rs 196.60 crore on 56% growth in net sales to Rs 4315.40 crore in the year ended 31 March 2016 (FY 2016) over the year ended 31 March 2015 (FY 2015). As of 31 March 2016, the company had order book of Rs 10800 crore. Government contracts accounted for 76.27% of the order book as on 31 March 2016.

Powered by Capital Market - Live News

Sun Pharma slides after uninspiring Q1 results from US subsidiary Taro Pharma
Aug 11,2016

Meanwhile, the S&P BSE Sensex was up 18.12 points or 0.07% at 27,793.

On BSE, so far 1.77 lakh shares were traded in the counter as against average daily volume of 2.87 lakh shares in the past one quarter. The stock hit a high of Rs 817 and a low of Rs 785.70 so far during the day. The stock had hit a 52-week low of Rs 706.40 on 24 November 2015. The stock had hit a 52-week high of Rs 965.15 on 20 August 2015. The stock had outperformed the market over the past one month till 10 August 2016, gaining 4.98% compared with 2.39% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, advancing 1.86% as against Sensexs 7.77% rise.

The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Rs 1.

Taro Pharmaceutical Industries (Taro Pharma) net profit rose 6.08% to $109.9 million on 8.6% increase in net sales to $233.8 million in Q1 June 2016 over Q1 June 2015. The quarter (Q1 June 2016) witnessed slight decrease in the volumes over corresponding previous period. Net sales in Q1 June 2015 were negatively impacted by a $14 million provision for price protections.

Kal Sundaram, Taros CEO stated that the companys increased R&D investment reflects its continuing focus on developing a strong product pipeline. Sales from new products are beginning to accelerate, however they continue to experience increased competitive intensity, Sundaram said.

Sun Pharmaceutical Industries is scheduled to announce Q1 June 2016 results tomorrow, 12 August 2016. The companys consolidated net profit rose 92.7% to Rs 1713.69 crore on 21.5% growth in net sales to Rs 7413.87 crore in Q4 March 2016 over Q4 March 2015.

Sun Pharmaceutical Industries is the worlds fifth largest specialty generic pharmaceutical company and Indias top pharmaceutical company.

Powered by Capital Market - Live News

Sun Pharma slides after uninspiring Q1 results from US subsidiary Taro
Aug 11,2016

Meanwhile, the S&P BSE Sensex was up 18.12 points or 0.07% at 27,793.

On BSE, so far 1.77 lakh shares were traded in the counter as against average daily volume of 2.87 lakh shares in the past one quarter. The stock hit a high of Rs 817 and a low of Rs 785.70 so far during the day. The stock had hit a 52-week low of Rs 706.40 on 24 November 2015. The stock had hit a 52-week high of Rs 965.15 on 20 August 2015. The stock had outperformed the market over the past one month till 10 August 2016, gaining 4.98% compared with 2.39% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, advancing 1.86% as against Sensexs 7.77% rise.

The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Rs 1.

Taro Pharmaceutical Industries (Taro Pharma) net profit rose 6.08% to $109.9 million on 8.6% increase in net sales to $233.8 million in Q1 June 2016 over Q1 June 2015. The quarter (Q1 June 2016) witnessed slight decrease in the volumes over corresponding previous period. Net sales in Q1 June 2015 were negatively impacted by a $14 million provision for price protections.

Kal Sundaram, Taros CEO stated that the companys increased R&D investment reflects its continuing focus on developing a strong product pipeline. Sales from new products are beginning to accelerate, however they continue to experience increased competitive intensity, Sundaram said.

Sun Pharmaceutical Industries is scheduled to announce Q1 June 2016 results tomorrow, 12 August 2016. The companys consolidated net profit rose 92.7% to Rs 1713.69 crore on 21.5% growth in net sales to Rs 7413.87 crore in Q4 March 2016 over Q4 March 2015.

Sun Pharmaceutical Industries is the worlds fifth largest specialty generic pharmaceutical company and Indias top pharmaceutical company.

Powered by Capital Market - Live News

Bank of Baroda tumbles after weak Q1 results
Aug 11,2016

The result was announced before trading hours today, 11 August 2016.

Meanwhile, the BSE Sensex was almost flat at 27,775.59.

On BSE, so far 20.41 lakh shares were traded in the counter, compared with average daily volume of 11.52 lakh shares in the past one quarter. The stock hit a high of Rs 153 and a low of Rs 146.40 so far during the day. The stock hit a 52-week high of Rs 216.25 on 18 August 2015. The stock hit a 52-week low of Rs 109.45 on 12 February 2016. The stock had underperformed the market over the past 30 days till 10 August 2016, falling 0.28% compared with 0.12% decline in the Sensex. The scrip had also underperformed the market in past one quarter, rising 1.65% as against Sensexs 7.70% rise.

The large-cap state-run bank has equity capital of Rs 460.83 crore. Face value per share is Rs 2.

The banks gross non-performing assets (NPAs) stood at Rs 42991.68 crore as on 30 June 2016 as against Rs 40521.04 crore as on 31 March 2016 and Rs 17273.95 crore as on 30 June 2015. The ratio of gross NPAs to gross advances stood at 11.15% as on 30 June 2016 as against 9.99% as on 31 March 2016 and 4.13% as on 30 June 2015. The ratio of net NPAs to net advances stood at 5.73% as on 30 June 2016 as against 5.06% as on 31 March 2016 and 2.07% as on 30 June 2015.

The banks provisions and contingencies (excluding tax provisions) surged 234.16% to Rs 2004.07 crore in Q1 June 2016 over Q1 June 2015. Provision coverage ratio of the bank was at 60.17% as on 30 June 2016.

Government of India holds 59.23% stake in Bank of Baroda (as on 30 June 2016).

Powered by Capital Market - Live News

Honda Siel Power gains as Reliance MF purchases bulk shares
Aug 11,2016

Meanwhile, the S&P BSE Sensex was up 21.11 points or 0.08% at 27,795.99.

On BSE, so far 509 shares were traded in the counter as against average daily volume of 2,854 shares in the past one quarter. The stock hit a high of Rs 1,274 and a low of Rs 1,225 so far during the day. The stock had hit a 52-week high of Rs 1,422 on 29 December 2015. The stock had hit a 52-week low of Rs 1,052.50 on 8 September 2015. The stock had underperformed the market over the past one month till 10 August 2016, sliding 0.41% compared with 2.39% rise in the Sensex. The scrip had also underperformed the market in past one quarter, declining 2.99% as against Sensexs 7.77% rise.

The small-cap company has equity capital of Rs 10.14 crore. Face value per share is Rs 10.

Reliance Capital Trustee Co Ltd A/C MF bought 1.28 lakh shares of Honda Siel Power Products at an average price of Rs 1,215 per share in a bulk deal on the BSE. Reliance Mutual Fund bought 2 lakh shares at an average price of Rs 1,215 per share in a bulk deal on the NSE.

Honda Siel Power Products net profit rose 6.3% to Rs 15.36 crore on 4.4% growth in net sales to Rs 190.20 crore in Q4 March 2016 over Q4 March 2015.

Honda Siel Power Products is a manufacturer of power products and is a subsidiary of Honda Motor Co. Japan.

Powered by Capital Market - Live News

Punj Lloyd gains as Q1 net loss narrows
Aug 11,2016

Meanwhile, the BSE Sensex was up 31.11 points, or 0.11%, to 27,805.99.

On BSE, so far 2.46 lakh shares were traded in the counter, compared with average daily volume of 3.08 lakh shares in the past one quarter. The stock hit a high of Rs 21.10 and a low of Rs 20.35 so far during the day. The stock hit a 52-week high of Rs 33.90 on 11 August 2015. The stock hit a record low of Rs 17.65 on 7 June 2016. The stock had underperformed the market over the past 30 days till 10 August 2016, falling 11.43% compared with 0.12% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 11.24% as against Sensexs 7.70% rise.

The small-cap company has equity capital of Rs 66.42 crore. Face value per share is Rs 2.

Punj Lloyd reported net loss of Rs 211.39 crore in Q1 June 2016, lower than net loss of Rs 581.84 crore in Q1 June 2015. Total income rose 45.5% to Rs 1010.17 crore in Q1 June 2016 over Q1 June 2015. The result was announced after market hours yesterday, 10 August 2016.

Earnings before interest, taxes, depreciation and amortization (EBITDA) was reported at Rs 36 crore Q1 June 2016 compared with loss of Rs 289 crore in Q1 June 2015.

The companys chairman and managing director, Atul Punj, said that the company improved its performance as a result of the turnaround efforts put in across various fronts. The order backlog remains strong at Rs 21618 crore and execution of all projects across geographies is progressing in line with defined timelines. The firm is seeing a gradually improving environment both in India and overseas and are optimistic of opportunities unfolding. The companys thrust is on improving the quality of its balance sheet, execution of projects, recovery of claims, cash flows and settling all legacy issues.

Punj Lloyd is a diversified international conglomerate offering engineering procurement construction (EPC) services in energy and infrastructure along with engineering and manufacturing capabilities in the defence sector.

Powered by Capital Market - Live News

Indiabulls Real Estate gains after good Q1 earnings
Aug 11,2016

The result was announced after market hours yesterday, 10 August 2016.

Meanwhile, the BSE Sensex was down 15.58 points, or 0.06%, to 27,759.30.

On BSE, so far 4.41 lakh shares were traded in the counter, compared with average daily volume of 19.35 lakh shares in the past one quarter. The stock hit a high of Rs 89.10 and a low of Rs 85.70 so far during the day. The stock hit a 52-week high of Rs 105.25 on 30 May 2016. The stock hit a 52-week low of Rs 42.25 on 12 February 2016. The stock had underperformed the market over the past 30 days till 10 August 2016, falling 11.18% compared with 0.12% decline in the Sensex. The scrip had also underperformed the market in past one quarter, rising 1.86% as against Sensexs 7.70% rise.

The mid-cap company has equity capital of Rs 101.13 crore. Face value per share is Rs 2.

Indiabulls Real Estates consolidated EBITDA (earnings before interest, taxes, depreciation and amortization), excluding non-operating income, rose 8.20% to Rs 299.63 crore in Q1 June 2016 over Q1 June 2015.

EBITDA margin (excluding non-operating income) was reported at 34.30% in Q1 June 2016 compared with 33.90% in Q1 June 2015.

Indiabulls Real Estate is a real estate development company with development projects spread across office and commercial complexes, premium residential developments, mega townships, retail spaces, hotel and resorts, special economic zones and infrastructure development.

Powered by Capital Market - Live News

Lupin inches up after securing final USFDA nod for electrotyte replenisher drug
Aug 11,2016

The announcement was made after market hours yesterday, 10 August 2016.

Meanwhile, the S&P BSE Sensex was down 55.33 points or 0.2% at 27,719.55.

On BSE, so far 17,000 shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter. The stock hit a high of Rs 1,567.60 and a low of Rs 1,551 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 10 August 2016, sliding 5.63% compared with 2.39% rise in the Sensex. The scrip had also underperformed the market in past one quarter, declining 4.31% as against Sensexs 7.77% rise.

The large-cap company has equity capital of Rs 90.20 crore. Face value per share is Rs 2.

Lupin announced that its US subsidiary Gavis Pharmaceuticals LLC, USA has received final approval for its Potassium Chloride Extended-Release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (USFDA). The drug is a generic equivalent of Upsher-Smith Labs Klor-Con Extended-Release Tablets, 8 mEq and 10 mEq. It is an electrotyte replenisher indicated for the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Klor-Con Extended-Release Tablets, 8 mEq and 10 mEq had annual US sales of $101.3 million as per IMS MAT June 2016 data.

Shares of Lupin had tanked 8.72% in the preceding two trading sessions to settle at Rs 1,545.05 yesterday, 10 August 2016 from its close of Rs 1,692.75 on 8 August 2016, after the companys announcement of Q1 June 2016 results during trading hours on 9 August 2016. Lupins consolidated net profit rose 55.1% to Rs 882 crore on 40% growth in net sales to Rs 4313.60 crore in Q1 June 2016 over Q1 June 2015.

A foreign brokerage has reportedly downgraded shares of the Indian drug maker to sell after the announcement of the first quarter results. The brokerage reportedly said that the competition in top US products will weigh on the companys growth. Lupins key complex products lack visibility of launch. Lupin is likely to post single digit earnings per share growth in the year ending March 2018, it added. Meanwhile, another foreign brokerage reportedly maintained underperform rating on Lupin. It reportedly said that risk-reward ratio is unfavourable for the stock. Q1 has been a peak profit quarter for Lupin. The brokerage cut its estimates on Lupins earnings per share for the year ending March 2017 (FY 2017).

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News

Lupin inches up after securing final FDA nod for electrotyte replenisher drug
Aug 11,2016

The announcement was made after market hours yesterday, 10 August 2016.

Meanwhile, the S&P BSE Sensex was down 55.33 points or 0.2% at 27,719.55.

On BSE, so far 17,000 shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter. The stock hit a high of Rs 1,567.60 and a low of Rs 1,551 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 10 August 2016, sliding 5.63% compared with 2.39% rise in the Sensex. The scrip had also underperformed the market in past one quarter, declining 4.31% as against Sensexs 7.77% rise.

The large-cap company has equity capital of Rs 90.20 crore. Face value per share is Rs 2.

Lupin announced that its US subsidiary Gavis Pharmaceuticals LLC, USA has received final approval for its Potassium Chloride Extended-Release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (USFDA) to market a generic equivalent of Upsher-Smith Labs Klor-Con Extended-Release Tablets, 8 mEq and 10 mEq. It is an electrotyte replenisher indicated for the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Klor-Con Extended-Release Tablets, 8 mEq and 10 mEq had US annual sales of $101.3 million as per IMS MAT June 2016.

Shares of Lupin had tanked 8.72% in the preceding two trading sessions to settle at Rs 1,545.05 yesterday, 10 August 2016 from its close of Rs 1,692.75 on 8 August 2016, after the companys announcement of Q1 June 2016 results during trading hours on 9 August 2016. Lupins consolidated net profit rose 55.1% to Rs 882 crore on 40% growth in net sales to Rs 4313.60 crore in Q1 June 2016 over Q1 June 2015.

A foreign brokerage has reportedly downgraded shares of the Indian drug maker to sell after the announcement of the first quarter results. The brokerage reportedly said that the competition in top US products will weigh on the companys growth. Lupins key complex products lack visibility of launch. Lupin is likely to post single digit earnings per share growth in the year ending March 2018, it added. Meanwhile, another foreign brokerage reportedly maintained underperform rating on Lupin. It reportedly said that risk-reward ratio is unfavourable for the stock. Q1 has been a peak profit quarter for Lupin. The brokerage cut its estimates on Lupins earnings per share for the year ending March 2017 (FY 2017).

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News

Lupin inches up after securing final USFDA nod for electrolyte replenisher drug
Aug 11,2016

The announcement was made after market hours yesterday, 10 August 2016.

Meanwhile, the S&P BSE Sensex was down 55.33 points or 0.2% at 27,719.55.

On BSE, so far 17,000 shares were traded in the counter as against average daily volume of 1.40 lakh shares in the past one quarter. The stock hit a high of Rs 1,567.60 and a low of Rs 1,551 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 10 August 2016, sliding 5.63% compared with 2.39% rise in the Sensex. The scrip had also underperformed the market in past one quarter, declining 4.31% as against Sensexs 7.77% rise.

The large-cap company has equity capital of Rs 90.20 crore. Face value per share is Rs 2.

Lupin announced that its US subsidiary Gavis Pharmaceuticals LLC, USA has received final approval for its Potassium Chloride Extended-Release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (USFDA). The drug is a generic equivalent of Upsher-Smith Labs Klor-Con Extended-Release Tablets, 8 mEq and 10 mEq. It is an electrolyte replenisher indicated for the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Klor-Con Extended-Release Tablets, 8 mEq and 10 mEq had annual US sales of $101.3 million as per IMS MAT June 2016 data.

Shares of Lupin had tanked 8.72% in the preceding two trading sessions to settle at Rs 1,545.05 yesterday, 10 August 2016 from its close of Rs 1,692.75 on 8 August 2016, after the companys announcement of Q1 June 2016 results during trading hours on 9 August 2016. Lupins consolidated net profit rose 55.1% to Rs 882 crore on 40% growth in net sales to Rs 4313.60 crore in Q1 June 2016 over Q1 June 2015.

A foreign brokerage has reportedly downgraded shares of the Indian drug maker to sell after the announcement of the first quarter results. The brokerage reportedly said that the competition in top US products will weigh on the companys growth. Lupins key complex products lack visibility of launch. Lupin is likely to post single digit earnings per share growth in the year ending March 2018, it added. Meanwhile, another foreign brokerage reportedly maintained underperform rating on Lupin. It reportedly said that risk-reward ratio is unfavourable for the stock. Q1 has been a peak profit quarter for Lupin. The brokerage cut its estimates on Lupins earnings per share for the year ending March 2017 (FY 2017).

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News